Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25440082 | 0.83 | KMT2A (0.60) | MAPTKMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL15133252 | 0.83 | MAPT (0.43) | MAPTKMT2AALDH1A1 | |
| SCHEMBL31197024 | 0.82 | KMT2A (0.53) | MAPTKMT2ASMN1; SMN2TSHRF2 | |
| SCHEMBL13898818 | 0.82 | ALDH1A1 (0.54) | MAPTKMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL29151822 | 0.77 | HRH3 (0.45) | MAPTSLC6A3 | |
| SCHEMBL9341204 | 0.77 | KMT2A (0.49) | MAPTKMT2ASMN1; SMN2TSHRF2 | |
| SCHEMBL6353529 | 0.76 | KMT2A (0.51) | MAPTKMT2ASMN1; SMN2TSHRF2 | |
| SCHEMBL30578029 | 0.75 | MAPT (0.57) | MAPTKMT2ASMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL15133254 | 0.74 | L3MBTL1 (0.45) | MAPTSMN1; SMN2LMNA | |
| SCHEMBL3143807 | 0.74 | KMT2A (0.53) | MAPTKMT2ASMN1; SMN2TSHRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | AMAR SALOMON (US) | 2023-11-30 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767283-B2 | Anti-inflammatory compounds | AMAR SALOMON (US) | 2023-09-26 | — | — | US | disclosed |
| US-7244692-B2 | Substituted benzoylcyclohexane diones for use as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2007-07-17 | — | — | US | disclosed |
| EP-1034159-B1 | PROCESS FOR THE PREPARATION OF ACYLATED CYCLIC 1,3-DICARBONYL COMPOUNDS | SYNGENTA LTD (GB) | 2003-01-22 | — | — | EP | disclosed |
| US-6218579-B1 | REARRANGEMENT OF CYCLOALKANONE ENOL ESTER IN PRESENCE OF AZOLE AND BASE | ZENECA LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |
| EP-1034159-A1 | PROCESS FOR THE PREPARATION OF ACYLATED CYCLIC 1,3-DICARBONYL COMPOUNDS | ZENECA LIMITED (GB) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999028282-A1 | PROCESS FOR THE PREPARATION OF ACYLATED CYCLIC 1,3-DICARBONYL COMPOUNDS | ZENECA LIMITED (GB) | 1999-06-10 | — | — | WO | disclosed |
| EP-0320864-A2 | 4-Benzoyl-3-hydroxy-5-oxo-3-cyclohexene-carboxylic-acid derivatives, process for their preparation and their use as plant growth-regulating agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382840-A1 | ANTI-INFLAMMATORY COMPOUNDS | TNF, IL1A, NFKBIA | MAPT 4746/4885KMT2A 786/4885SMN1; SMN2 4809/4885 |
| US-11767283-B2 | Anti-inflammatory compounds | TNF, IL1A, NFKBIA | MAPT 4734/4885KMT2A 815/4885SMN1; SMN2 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.